Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2022-11-06 Capital/Financing Update
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Cleansing Notice - Placement and Share Purchase Plan 3 pages 225.3KB
Capital/Financing Update Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act 2001 and ASIC Corporations Instrument 2019/547 regarding the issue of new shares and a share purchase plan. It provides legal and regulatory information about the share issuance and the exemption from disclosure requirements. The document is an announcement related to capital raising activities, specifically the issuance of shares and a share purchase plan, rather than a full financial report or detailed financial data. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 6175 characters, which is sufficient for a detailed announcement but does not contain financial statements or management discussion typical of reports like Annual or Interim Reports.
2022-11-06 English
Data Presentation-American Society of Nephrology Conference 3 pages 253.6KB
Investor Presentation Classification · 90% confidence The document is an announcement dated 4 November 2022 from Botanix Pharmaceuticals about an upcoming presentation at the American Society of Nephrology Annual Meeting (ASN 2022). It details the topic of the presentation, the author, and the timing of the event. The content focuses on the announcement of a presentation of an abstract at a conference, not the presentation materials themselves or a detailed report. There are no financial statements, regulatory filings, or detailed financial data included. The document is essentially a press release announcing an upcoming investor-related event (presentation). This fits best under the category of Investor Presentation (IP) announcements, as it informs investors about a forthcoming presentation focusing on clinical and research data relevant to the company’s business and pipeline. The document is not the presentation itself but an announcement of it, which aligns with the Investor Presentation category rather than a report publication announcement or regulatory filing. Confidence is high given the clear nature of the announcement and its content.
2022-11-03 English
Letter/ Supplementary Notice of AGM/Proxy Form 9 pages 473.5KB
AGM Information Classification · 95% confidence The document is a Supplementary Notice of Annual General Meeting (AGM) for Botanix Pharmaceuticals Limited, dated 3 November 2022. It discusses additional resolutions (25 and 26) related to the ratification and approval of share issues to Antares Capital, which are to be considered at the AGM scheduled for 23 November 2022. The document includes proxy form instructions and detailed explanatory notes about the share issuance and shareholder voting procedures. It is clearly a notice and supplementary information for an upcoming AGM, not the AGM presentation materials themselves, nor the voting results or the actual meeting minutes. Therefore, the document fits the category of AGM Information (AGM-R), as it is related to the AGM meeting materials and notices.
2022-11-02 English
A$5 million Institutional Placement and Share Purchase Plan 4 pages 265.8KB
Capital/Financing Update Classification · 100% confidence The document is an announcement dated 31 October 2022 from Botanix Pharmaceuticals regarding a commitment to raise A$5 million via an institutional placement and a Share Purchase Plan (SPP). It details the terms of the placement, the use of proceeds, and the timetable for the offering and related shareholder meeting. The content focuses on fundraising activities, share issuance, and capital raising plans. There are no financial statements or detailed financial performance data included, nor is this a report or transcript. The document is clearly an update on capital raising activities and changes to the company's capital structure. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (10,394 characters) supports that this is a full announcement rather than a brief notice or report publication announcement.
2022-10-30 English
Proposed issue of securities - BOT 7 pages 31.4KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Botanix Pharmaceuticals Ltd regarding a proposed issue of securities under a securities purchase plan. It details the number of securities to be issued, offer conditions, pricing, timetable, and other related information. The content focuses on the company's capital raising activity and changes to its capital structure. There are no financial statements or comprehensive financial performance data included, so it is not an Annual Report or Interim Report. It is not a report publication announcement since it contains substantive details about the capital raising. The document fits the definition of a Capital/Financing Update, which covers updates on company fundraising and capital structure changes.
2022-10-30 English
Proposed issue of securities - BOT 5 pages 27.9KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Botanix Pharmaceuticals Ltd regarding a proposed issue of securities, specifically a placement of ordinary fully paid shares. It includes details such as the number of securities to be issued, issue price, proposed issue date, conditions including shareholder approval, and fees related to the placement. The content is focused on informing the market and shareholders about the capital raising activity and the terms of the proposed securities issuance. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not a full financial report, earnings release, or regulatory filing unrelated to capital changes. Therefore, the appropriate classification is CAP with high confidence.
2022-10-30 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.